Delivery Strategies for Immune Checkpoint Blockade
The DOI matches its Crossref record; 94 of the 94 references it cites were found in a registry or an index.
Abstract
Immune checkpoint blockade, which blocks the regulatory pathways that express on immune cells to improve antitumor immunological responses, is becoming one of the most promising approaches for antitumor therapy. This therapy has achieved important clinical advancement and provided a new opportunity against a variety of cancers. However, limitations of checkpoint inhibitors application, including the risk of autoimmune disease, low objective response rates, and high cost, still largely affect their broad applications in patients. Therefore, it is desirable to seek effective delivery methods to further enhance the therapeutic efficacy and reduce drawbacks of immune checkpoint blockade. This brief review summarizes strategies to increase the antitumor immunity, including the local and targeted delivery of checkpoint inhibitors, and a combination of different checkpoint inhibitors or with other therapeutic treatments.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Immune checkpoint inhibition consists in the administration of therapeutic agents able to block the immune-inhibitory pathway, thus modulating T cell activation against tumor target cells.”
From Gut Microbiota and Cancer: From Pathogenesis to Therapy (2019) · cites this paper as [173]
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Stupp, R., Hegi, M. E., Mason, W. P., van den Bent, M. J., Taphoorn, M. J., Janzer, R. C., Ludwin, S. K., Allgeier, A., Fisher, B., Belanger, K., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70025-7 · Cited by 7,668
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474
Autophagy fights disease through cellular self-digestion
Mizushima, N., Levine, B., Cuervo, A. M., & Klionsky, D. J. (2008) · Nature · doi:10.1038/nature06639 · Cited by 6,452
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Kuiper, G. G. J. M., Carlsson, B., Grandien, K., Enmark, E., Häggblad, J., Nilsson, S., & Gustafsson, J.-A. (1997) · Endocrinology · doi:10.1210/endo.138.3.4979 · Cited by 4,442
Restoring function in exhausted CD8 T cells during chronic viral infection
Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H., Freeman, G. J., & Ahmed, R. (2006) · Nature · doi:10.1038/nature04444 · Cited by 3,986
Cancer immunotherapy comes of age
Mellman, I., Coukos, G., & Dranoff, G. (2011) · Nature · doi:10.1038/nature10673 · Cited by 3,893
Research works printed but not linked: 1
- Qi Q., 2016, Cancer ‐ Am. Cancer Soc., 122, 2158
Cited by
Huang, L., Li, Y., Du, Y., Zhang, Y., Wang, X., Ding, Y., Yang, X., Meng, F., Tu, J., Luo, L., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12771-9 · Cited by 596
Gut Microbiota and Cancer: From Pathogenesis to Therapy
Vivarelli, S., Salemi, R., Candido, S., Falzone, L., Santagati, M., Stefani, S., Torino, F., Banna, G. L., Tonini, G., & Libra, M. (2019) · Cancers · doi:10.3390/cancers11010038 · Cited by 586
Chen, C., Ni, X., Jia, S., Liang, Y., Wu, X., Kong, D., & Ding, D. (2019) · Advanced Materials · doi:10.1002/adma.201904914 · Cited by 503
Recent Advances in Hyperthermia Therapy‐Based Synergistic Immunotherapy
Chang, M., Hou, Z., Wang, M., Li, C., & Lin, J. (2021) · Advanced Materials · doi:10.1002/adma.202004788 · Cited by 450
Local biomaterials-assisted cancer immunotherapy to trigger systemic antitumor responses
Chen, Q., Chen, M., & Liu, Z. (2019) · Chemical Society Reviews · doi:10.1039/c9cs00271e · Cited by 288
Self-citationTransdermal cold atmospheric plasma-mediated immune checkpoint blockade therapy
Chen, G., Chen, Z., Wen, D., Wang, Z., Li, H., Zeng, Y., Dotti, G., Wirz, R. E., & Gu, Z. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1917891117 · Cited by 271
Self-citationAdvances in nanomedicine for cancer starvation therapy
Yu, S., Chen, Z., Zeng, X., Chen, X., & Gu, Z. (2019) · Theranostics · doi:10.7150/thno.38261 · Cited by 242
Self-citationNanoparticle-Mediated Remodeling of the Tumor Microenvironment to Enhance Immunotherapy
Musetti, S., & Huang, L. (2018) · ACS Nano · doi:10.1021/acsnano.8b05893 · Cited by 239
Engineering PD-1-Presenting Platelets for Cancer Immunotherapy
Zhang, X., Wang, J., Chen, Z., Hu, Q., Wang, C., Yan, J., Dotti, G., Huang, P., & Gu, Z. (2018) · Nano Letters · doi:10.1021/acs.nanolett.8b02321 · Cited by 232
Self-citationRecent advances in overcoming barriers to cell‐based delivery systems for cancer immunotherapy
Ding, Y., Wang, Y., & Hu, Q. (2022) · Exploration · doi:10.1002/exp.20210106 · Cited by 212
Self-citationEngineering the drug carrier biointerface to overcome biological barriers to drug delivery
Finbloom, J. A., Sousa, F., Stevens, M. M., & Desai, T. A. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.007 · Cited by 188
Emerging Nano‐/Microapproaches for Cancer Immunotherapy
Mi, Y., Hagan, C. T., Vincent, B. G., & Wang, A. Z. (2019) · Advanced Science · doi:10.1002/advs.201801847 · Cited by 177
Wang, M., Chang, M., Zheng, P., Sun, Q., Wang, G., Lin, J., & Li, C. (2022) · Advanced Science · doi:10.1002/advs.202202332 · Cited by 172
Local and Targeted Delivery of Immune Checkpoint Blockade Therapeutics
Han, X., Li, H., Zhou, D. R., Chen, Z., & Gu, Z. (2020) · Accounts of Chemical Research · doi:10.1021/acs.accounts.0c00339 · Cited by 155
Self-citationNguyen, T. L., Cha, B. G., Choi, Y., Im, J., & Kim, J. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.119859 · Cited by 142
Xing, L., Gong, J., Wang, Y., Zhu, Y., Huang, Z., Zhao, J. Y., Li, F., Wang, J.-H., Wen, H., & Jiang, H. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.03.027 · Cited by 129
Bioresponsive Protein Complex of aPD1 and aCD47 Antibodies for Enhanced Immunotherapy
Chen, Q., Chen, G., Chen, J., Shen, J., Zhang, X., Wang, J., Chan, A., & Gu, Z. (2019) · Nano Letters · doi:10.1021/acs.nanolett.9b00584 · Cited by 122
Self-citationAlsaiari, S. K., Qutub, S., Sun, S., Baslyman, W. S., Aldehaiman, M. M., Alyami, M., Almalik, A., Halwani, R., Merzaban, J. S., Mao, Z., et al. (2021) · Science Advances · doi:10.1126/sciadv.abe7174 · Cited by 112
Advancement of cancer immunotherapy using nanoparticles-based nanomedicine
Gowd, V., Ahmad, A., Tarique, M., Suhail, M., Zughaibi, T. A., Tabrez, S., & Khan, R. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.03.026 · Cited by 112
Ultrathin Metal-Organic-Layer Mediated Radiotherapy-Radiodynamic Therapy
Ni, K., Lan, G., Chan, C., Duan, X., Guo, N., Veroneau, S. S., Weichselbaum, R. R., & Lin, W. (2019) · Matter · doi:10.1016/j.matt.2019.06.007 · Cited by 107
Boosting Checkpoint Immunotherapy with Biomaterials
Liu, L., Pan, Y., Zhao, C., Huang, P., Chen, X. S., & Rao, L. (2023) · ACS Nano · doi:10.1021/acsnano.2c11691 · Cited by 100
Polymeric PD-L1 blockade nanoparticles for cancer photothermal-immunotherapy
Yu, Y., Li, J., Song, B., Ma, Z., Zhang, Y., Sun, H., Wei, X., Bai, Y., Lu, X., Zhang, P., et al. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.121312 · Cited by 90
Wang, Y., Shi, J., Xin, M., Kahkoska, A. R., Wang, J., & Gu, Z. (2024) · Nature Biomedical Engineering · doi:10.1038/s41551-024-01230-6 · Cited by 88
Self-citationFang, T., Cao, X., Shen, B., Chen, Z., & Chen, G. (2023) · Biomaterials · doi:10.1016/j.biomaterials.2023.122189 · Cited by 83
Self-citationNucleic Acid-Based Approaches for Tumor Therapy
Hager, S., Fittler, F. J., Wagner, E., & Bros, M. (2020) · Cells · doi:10.3390/cells9092061 · Cited by 81
Advances in engineering local drug delivery systems for cancer immunotherapy
Abdou, P., Wang, Z., Chen, Q., Chan, A., Zhou, D. R., Gunadhi, V., & Gu, Z. (2020) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1632 · Cited by 78
Self-citationYuan, C.-S., Deng, Z., Qin, D., Mu, Y., Chen, X., & Liu, Y. (2021) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.02.030 · Cited by 73
Wang, Y., Zhou, S., Wang, Y., Lu, Z.-D., Zhang, Y., Xu, C., & Wang, J. (2023) · Nature Communications · doi:10.1038/s41467-023-37656-w · Cited by 72
(2022) · doi:10.1016/j.hsr.2021.100010 · Cited by 69
Gut Microbiota and Lung Injury
Tan, J.-Y., Tang, Y., & Huang, J. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-2385-4_5 · Cited by 68
Song, Z., Luo, W., Zheng, H., Zeng, Y., Wang, J., & Chen, T. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202100149 · Cited by 67
Jung, M., Kang, M., Kim, B., Hong, J., Kim, C., Koh, C., Choi, G., Chung, Y., & Kim, B. (2022) · Advanced Materials · doi:10.1002/adma.202106516 · Cited by 63
Benefits of using probiotics as adjuvants in anticancer therapy (Review)
Vivarelli, S., Falzone, L., Basile, M. S., Nicolosi, D., Genovese, C., Libra, M., & Salmeri, M. (2019) · World Academy of Sciences Journal · doi:10.3892/wasj.2019.13 · Cited by 57
Oral Delivery of Therapeutic Antibodies with a Transmucosal Polymeric Carrier
Zhu, W., Chao, Y., Jin, Q., Chen, L., Shen, J., Zhu, J., Chai, Y., Lu, P., Yang, N., Chen, M., et al. (2023) · ACS Nano · doi:10.1021/acsnano.2c09266 · Cited by 57
Self-citationChoi, B., Jung, H., Yu, B., Choi, H., Lee, J., & Kim, D. (2019) · Small · doi:10.1002/smll.201904378 · Cited by 55
Recent Advances in Polymeric Nanomedicines for Cancer Immunotherapy
Lee, E. S., Shin, J. M., Son, S., Ko, H., Um, W., Song, S. H., Lee, J. A., & Park, J. H. (2019) · Advanced Healthcare Materials · doi:10.1002/adhm.201801320 · Cited by 54
Manoharan, D., Wang, L., Chen, Y., Li, W., & Yeh, C. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202400746 · Cited by 52
Biohybrid Vaccines for Improved Treatment of Aggressive Melanoma with Checkpoint Inhibitor
Fontana, F., Fusciello, M., Groeneveldt, C., Capasso, C., Chiaro, J., Feola, S., Liu, Z., Mäkilä, E. M., Salonen, J., Hirvonen, J. J., et al. (2019) · ACS Nano · doi:10.1021/acsnano.8b09613 · Cited by 52
Controlled release of immunotherapeutics for enhanced cancer immunotherapy after local delivery
Jin, Q., Liu, Z., & Chen, Q. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.10.019 · Cited by 46
Self-citationKim, J., Francis, D. M., & Thomas, S. N. (2021) · Nanomaterials · doi:10.3390/nano11020471 · Cited by 46
Nanomaterials as Smart Immunomodulator Delivery System for Enhanced Cancer Therapy
Yuan, C.-S., Liu, Y., Wang, T., Sun, M., & Chen, X. (2020) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.0c00804 · Cited by 46
Cao, Y., Ding, S., Zeng, L., Miao, J., Wang, K., Chen, G., Li, C., Zhou, J., Bian, X., & Tian, G. (2021) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.1c07626 · Cited by 45
Self-citationRajora, A. K., Ahire, E. D., Rajora, M. A. K., Singh, S., Bhattacharya, J., & Zhang, H. (2024) · Smart Medicine · doi:10.1002/smmd.20230035 · Cited by 43
Chang, H., Wen, X., Li, Z., Ling, Z., Zheng, Y., & Xu, C. (2022) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10457 · Cited by 41
Jiang, S., Liu, C., He, Q., Dang, K., Zhang, W., & Tian, Y. (2023) · Nano Research · doi:10.1007/s12274-023-5477-5 · Cited by 36
The application of immune checkpoint blockade in breast cancer and the emerging role of nanoparticle
Masoumi, E., Tahaghoghi-Hajghorbani, S., Jafarzadeh, L., Sanaei, M., Pourbagheri‐Sigaroodi, A., & Bashash, D. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.10.018 · Cited by 35
Hopkins, C. M., Javius-Jones, K., Wang, Y., Hong, H., Hu, Q., & Hong, S. (2022) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2022.2112569 · Cited by 32
Self-citationMei, E., Chen, C., Li, C., Ding, X., Chen, J., Xi, Q., Zhou, S., Liu, J., & Li, Z. (2021) · Biomacromolecules · doi:10.1021/acs.biomac.1c01279 · Cited by 31
Functional Nanomaterials Optimized to Circumvent Tumor Immunological Tolerance
Gong, N., Zhang, Y., Zhang, Z., Li, X., & Liang, X. (2018) · Advanced Functional Materials · doi:10.1002/adfm.201806087 · Cited by 29
Li, X., Luo, L., Jiang, M., Zhu, C., Shi, Y., Zhang, J., Qin, B., Luo, Z., Guo, X., Lu, Y., et al. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.05.002 · Cited by 29
Immune Checkpoint Inhibitors: Recent Clinical Advances and Future Prospects
Banday, A. H., & Abdalla, M. (2022) · Current Medicinal Chemistry · doi:10.2174/0929867329666220819115849 · Cited by 27
Nanotechnologies for enhancing cancer immunotherapy
Yang, J., Wang, C., Shi, S., & Dong, C. (2020) · Nano Research · doi:10.1007/s12274-020-2904-8 · Cited by 27
Self-citationClinical Relevance of Targeted Therapy and Immune-Checkpoint Inhibition in Lung Cancer
Leone, G. M., Candido, S., Lavoro, A., Vivarelli, S., Gattuso, G., Călina, D. C., Libra, M., & Falzone, L. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041252 · Cited by 26
Cytokine Therapy Combined with Nanomaterials Participates in Cancer Immunotherapy
Lian, H., Ma, S., Zhao, D., Zhao, W., Cui, Y., Hua, Y., & Zhang, Z. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14122606 · Cited by 26
Engineering Protein Delivery Depots for Cancer Immunotherapy
Wen, D., Chen, G., Chen, Q., Li, P. Y., Cheng, H., & Gu, Z. (2019) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.9b00061 · Cited by 26
Self-citationYe, J., Yu, Y., Li, Y., Yao, B., Gu, M., Yang, L., & Yin, S. (2024) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.4c05334 · Cited by 25
Li, Y., Tang, K., Zhang, X., Pan, W., Li, N., & Tang, B. (2022) · Chemical Science · doi:10.1039/d1sc03525h · Cited by 25
Aptamer-Gold Nanocage Composite for Photoactivated Immunotherapy
Song, W. L., Hu, J., Song, S., Xu, Y., Yang, H., Yang, F., Zhou, Y., Tao, Y., & Qiu, W. (2022) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.2c11089 · Cited by 25
Multifunctional Nanomodulators Regulate Multiple Pathways To Enhance Antitumor Immunity
Zheng, Y., Zhang, Z., Liu, Q., Zhao, Y., Zheng, C., Hao, J., Yi, K., Wang, Y., Wang, C., Zhao, X., et al. (2020) · ACS Applied Bio Materials · doi:10.1021/acsabm.0c00513 · Cited by 24
Self-citationChen, X., Ding, W., Jiang, Y., Shi, W., Qiu, Y., Zhao, H., & Luo, X. (2024) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.4c12603 · Cited by 23
A Shear-Thinning Biomaterial-Mediated Immune Checkpoint Blockade
Wu, Q., Qu, M., Kim, H., Zhou, X., Jiang, X., Chen, Y., Zhu, J., Ren, L. M., Wolter, T., Kang, H., et al. (2022) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.2c06137 · Cited by 20
Self-citationCheckpoint inhibitors: What gastroenterologists need to know
Ahmed∥, M. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i48.5433 · Cited by 18
Host Microbiomes in Tumor Precision Medicine: How far are we?
D’Amico, F., Barone, M., Tavella, T., Rampelli, S., Brigidi, P., & Turroni, S. (2022) · Current Medicinal Chemistry · doi:10.2174/0929867329666220105121754 · Cited by 17
Biomaterial-Based Sustained-Release Drug Formulations for Localized Cancer Immunotherapy
Mujahid, K., Rana, I., Suliman, I. H., Li, Z., Wu, J., He, H., & Nam, J. (2023) · ACS Applied Bio Materials · doi:10.1021/acsabm.3c00808 · Cited by 16
Displacement Affinity Release of Antibodies from Injectable Hydrogels
Huynh, V. A., & Wylie, R. G. (2019) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.9b12572 · Cited by 16
Monahan, D. S., Almas, T., Wyile, R., Cheema, F. H., Duffy, G. P., & Hameed, A. (2021) · Drug Delivery and Translational Research · doi:10.1007/s13346-020-00885-3 · Cited by 15
Improved Efficacy of Antibody Cancer Immunotherapeutics through Local and Sustained Delivery
Huynh, V. A., Jesmer, A. H., Shoaib, M. M., D'Angelo, A. D., Rullo, A. F., & Wylie, R. G. (2019) · ChemBioChem · doi:10.1002/cbic.201800579 · Cited by 14
Application of nanoscale metal–organic frameworks in tumor immunotherapy
Zeng, X., Lu, J.-S., Ma, D., Huang, Y., Chen, L., Wang, G., Chen, Q., & Lin, N. (2024) · Rare Metals · doi:10.1007/s12598-024-02779-6 · Cited by 14
Self-citationGene-guided OX40L anchoring to tumor cells for synergetic tumor “self-killing” immunotherapy
Lin, L., Hu, Y., Guo, Z., Chen, J., Sun, P., Tian, H., & Chen, X. (2022) · Bioactive Materials · doi:10.1016/j.bioactmat.2022.07.008 · Cited by 13
Role of the Microbiome in the Diagnosis and Management of Gastroesophageal Cancers
Mascaretti, F., Haider, S., Amoroso, C., Caprioli, F., Ramai, D., & Ghidini, M. (2024) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-024-01021-x · Cited by 12
Gao, L., Yuan, Z., Ma, N., Zhou, X. Y., Huang, X., Chen, W., & Qiao, H. (2024) · Chemical Engineering Journal · doi:10.1016/j.cej.2024.149688 · Cited by 12
Recent Advance of Nanomaterial-Mediated Tumor Therapies in the Past Five Years
Hao, X., Wu, J., Xiang, D., & Yang, Y. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.846715 · Cited by 12
Recent progress in topical and transdermal approaches for melanoma treatment
Yourdkhani, A., Esfandyari‐Manesh, M., Ranjbaran, P., Amani, M., & Dinarvand, R. (2024) · Drug Delivery and Translational Research · doi:10.1007/s13346-024-01738-z · Cited by 12
Immunotherapy of tumors by tailored nano-zeolitic imidazolate framework protected biopharmaceuticals
Dutta, S. (2021) · Biomaterials Science · doi:10.1039/d1bm01161h · Cited by 11
Li, Z., Liang, D., Huo, M., Guan, L., Liu, Z., Gu, F., Guan, X., & Chen, L. (2025) · Biomaterials Advances · doi:10.1016/j.bioadv.2025.214552 · Cited by 10
Li, Y., Ni, K., Chan, C., Guo, N., Luo, T., Han, W., Culbert, A. A., Weichselbaum, R. R., & Lin, W. (2021) · Advanced Therapeutics · doi:10.1002/adtp.202100160 · Cited by 9
Singh, D., & Bedi, N. (2025) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.70036 · Cited by 8
Prevention of cancer initiation by augmenting MHC-I antigen presentation via EZH2 inhibition
Ding, W., Ding, Z., Zeng, Q., Qiu, Y., Donnelly, C. R., Wu, Y., Jiang, Y., Han, Q., Xu, H. Y., Hao, C., et al. (2025) · Oncogene · doi:10.1038/s41388-025-03646-z · Cited by 8
Self-citationHuynh, V. A., Tatari, N., Marple, A. S. T., Savage, N. J., McKenna, D., Venugopal, C., Singh, S. K., & Wylie, R. G. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.05.040 · Cited by 8
Role of gut microbiota in tumorigenesis and antitumoral therapies: an updated review
Singhal, S., Bhadana, R., Jain, B. P., Gautam, A., Pandey, S., & Rani, V. (2023) · Biotechnology and Genetic Engineering Reviews · doi:10.1080/02648725.2023.2166268 · Cited by 7
Banday, A. H., Manzoor, M. M., Nissar, U., & Jaleel, S. (2026) · Scandinavian Journal of Immunology · doi:10.1111/sji.70084 · Cited by 7
Novel insight into the role of immunotherapy in gastrointestinal cancer (Review)
Liu, Y., Chen, J., Xu, Y., & Sun, Q. (2022) · Molecular and Clinical Oncology · doi:10.3892/mco.2022.2590 · Cited by 7
Development of nano-immunotherapy for cancer treatment: achievements and scopes
Raj, A., Babu, A., Kothandan, V. K., Park, I., & Hwang, S. R. (2023) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-023-00644-9 · Cited by 6
Heterogeneity-optimized method for predicting immune checkpoint blockade response
Liang, J., Guo, Q., Xiang, S., Wang, Y., & Li, J. (2025) · Scientific Reports · doi:10.1038/s41598-025-17718-3 · Cited by 5
Guo, H., Wu, H., Li, J., & Li, R. (2025) · American Journal of Case Reports · doi:10.12659/ajcr.947730 · Cited by 2
Delivery strategies for immune checkpoint blockade
Zhu, R., Lang, T., Yin, Q., & Li, Y. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-85781-9.00001-4 · Cited by 1
Cancer Immunotherapy Strategies: Basic Principles
Chongsathidkiet, P., Polania, J. W., Lorrey, S., Grabowski, M. M., Sankey, E. W., Wilkinson, D. S., & Fecci, P. E. (2021) · Bioanalysis · doi:10.1007/978-3-030-78338-9_2 · Cited by 1
GUT MICROBIOME IN CANCER: THE NEXT BIG OPPORTUNITY FOR BETTER PATIENT OUTCOMES?
Povšin, J., Sotošek, T., Novak, M., & Breznik, B. (2025) · Slovenian Veterinary Research · doi:10.26873/svr-2029-2024
Inam, M., Hayat, M., Latif, F., Ahmed, B., & Osman, A. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1953410
Microneedle-Enabled Exosome Therapy: From Tumor Targeting to Precision Treatment of Complex Diseases
Fang, Y., Song, H., Li, D., Jiang, Y., Zhao, K., Qiu, X., Zhao, C., Yu, X., Li, Y., & Song, X. (2026) · International Journal of Nanomedicine · doi:10.2147/ijn.s631632
Atabani, S. (2023) · Nottingham ePrints (University of Nottingham)
Gonçalves, N. M. F. (2021) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Metadata
- Authors
- Chen, Q., Wang, C., Chen, G., Hu, Q., & Gu, Z.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- Corresponding author
- Gu, Zhen
- Venue
- Advanced Healthcare Materials
- Publisher
- Wiley
- Published
- 2018-07-05
- Volume
- 7
- Issue
- 20
- Pages
- e1800424-e1800424
- ISSN
- 2192-2640 (ISSN-L)
- 2192-2659
- OpenAlex
- W2861806171
- Cited by
- 90
- References
- 94
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 9 · 2023: 9 · 2022: 16 · 2021: 16 · 2020: 12 · 2019: 16 · 2018: 5
- FWCI
- 1.28
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Advanced Healthcare Materials (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Alfred P. Sloan Foundation
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
- Keywords
- immune checkpoint blockade, drug delivery methods, targeted drug delivery, local drug delivery, combination therapy, antitumor immunity, immune checkpoint inhibitors, autoimmune adverse effects, cancer immunotherapy
- MeSH terms
- Autoimmune Diseases, Humans, Immunotherapy, Neoplasms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.